Surachat Jaroonpipatkul

Dr. Surachat Jaroonpipatkul


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TATanawat Attachaipanich
Tanawat Attachaipanich
BTBen Thiravetyan
Ben Thiravetyan
NTNarisara Tribuddharat
Narisara Tribuddharat
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
LNLeenhapong Navaravong
Leenhapong Navaravong
Premature ventricular complexes (PVCs) are commonly encountered problems in clinical settings. The range of symptoms can be from asymptomatic to palpitations, fatigue, or heart failure symptoms. A higher burden of PVCs is a risk factor for development of PVC-induced cardiomyopathy (PIC). Rhythm evaluation by 12-lead ECG and an ambulatory monitoring device are essential. Currently, several imaging modalities, such as echocardiography and cardiac magnetic resonance imaging, are utilized to evaluate the underlying structure that may be related to PIC. Beta blockers and antiarrhythmic drugs are typically part of the initial management strategy. If these fail, catheter ablation of PVCs is typically the next step. The purpose of this article is to summarize the current evidence/knowledge about PIC.

26 November 2025 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
AKAndrea N. Keithler
Andrea N. Keithler
TSThipsukhon Sathapanasiri
Thipsukhon Sathapanasiri
HTHarikrishna Tandri
Harikrishna Tandri
TBT. Jared Bunch
T. Jared Bunch
KKKlitos Konstantinidis
Klitos Konstantinidis
Background: Conventional substrate mapping for scar‐related ventricular tachycardia (VT) often fails to fully delineate critical arrhythmogenic components. Functional mapping strategies using extrastimuli have shown promise but are limited by procedural complexity. Methods: In total, 57 patients undergoing VT ablation between March 2023 and October 2024 were included in the study. Patients were grouped based on whether targeted double extrastimuli mapping (focused DEMAP) was used to guide mapping and ablation. Mapping was performed using EnSite X with omnipolar technology. Clinical and procedural outcomes were compared between focused DEMAP and non‐DEMAP groups with outcomes follow‐up at 12 months. Results: Focused DEMAP revealed a significantly higher correlation between DZs and VT critical isthmuses compared to sinus rhythm mapping (75.9% vs. 37.1%, p = 0.01). VT‐free survival at 12 months was higher in the DEMAP group (88.03%) than in the non‐DEMAP group (58.10%, p = 0.04). Trends also favored DEMAP in reducing cardiovascular hospitalization (10.55% vs. 24.70%) and mortality, though not statistically significant. Overall procedure time was similar mainly driven by less time during ablation and a lower mean ablated area in the focused DEMAP group compared to the non‐DEMAP group. Conclusion: The focused DEMAP, a focused double extrastimulus mapping strategy, enhances VT substrate identification and is associated with improved VT‐free survival without prolonging procedure time. This approach may refine substrate‐based ablation and optimize lesion targeting without increasing procedural burden.

28 February 2024 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
ATAngkawipa Trongtorsak
Angkawipa Trongtorsak
BBbyron Bolton
byron Bolton
STSittinun Thangjui
Sittinun Thangjui
APApichai Pokawattana
Apichai Pokawattana
LNLeenhapong Navaravong
Leenhapong Navaravong
Click on the article title to read more.

20 August 2025
Verified
Preprint
Open access
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
AKAndrea N. Keithler
Andrea N. Keithler
TSThipsukhon Sathapanasiri
Thipsukhon Sathapanasiri
HTHarikrishna Tandri
Harikrishna Tandri
TBThomas Jared Bunch
Thomas Jared Bunch
KKKlitos Konstantinidis
Klitos Konstantinidis
Background : Conventional substrate mapping for scar-related ventricular tachycardia (VT) often fails to fully delineate critical arrhythmogenic components. Functional mapping strategies using extrastimuli have shown promise but are limited by procedural complexity. Methods: 57 patients undergoing VT ablation between March 2023 and October 2024 were included in the study. Patients were grouped based on whether targeted double extrastimuli mapping (focused DEMAP) was used to guide mapping and ablation. Mapping was performed using EnSite X with omnipolar technology. Clinical and procedural outcomes were compared between focused DEMAP and non-DEMAP groups with outcomes follow up at 12 months. Results: Focused DEMAP revealed a significantly higher correlation between DZs and VT critical isthmuses compared to sinus rhythm mapping (75.9% vs. 37.1%, p = 0.01). VT-free survival at 12 months was higher in the DEMAP group (88.03%) than in the non-DEMAP group (58.10%, p = 0.04). Trends also favored DEMAP in reducing cardiovascular hospitalization (10.55% vs. 24.70%) and mortality, though not statistically significant. Overall procedure time was similar mainly driven by less time during ablation and lower mean ablated area in the focused DEMAP group compared to the non-DEMAP group. Conclusion: The focused DEMAP, a focused double extrastimulus mapping strategy, enhances VT substrate identification and is associated with improved VT-free survival without prolonging procedure time. This approach may refine substrate-based ablation and optimize lesion targeting without increasing procedural burden.

24 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
TST Sathapanasiri
T Sathapanasiri
APA Pokawattana
A Pokawattana
LNL Navaravong
L Navaravong
Background: Atrial fibrillation (AF) in individuals with cardiac implantable electronic devices is associated with heightened risks of adverse outcomes. Despite this, risk stratification for AF development in this patient cohort remains unexplored. Consequently, we present the development and validation of a simplified multi-parameter risk-based scoring system for predicting AF in patients with cardiac implantable electronic devices. Methods and Results: A cohort of 226 consecutive patients with cardiac implantable electronic devices at Rajavithi Hospital underwent comprehensive follow-up to observe AF development, defined by 12-lead EKG evidence of AF. Analysis encompassed risk factors and AF incidence. The resulting V-DASH score integrated a History of vascular disease, including coronary artery disease (CAD) and peripheral arterial disease (PAD) (1.5 points), Diabetes (1 point), Apical lead position (1 point), Sex (female gender (1.5 points)), and Hypertension (1 point). Predictive value assessment revealed that Diabetes, Female gender, and a history of vascular disease were significantly associated with AF incidence. Apical lead position and Hypertension emerged as robust risk factors for AF development. Over a median follow-up duration of 13 months, 8 (3.53%) patients developed AF. The incidence of AF exhibited a noteworthy escalation in correlation with the V-DASH score (4.68 times higher risk per point increase). Among patients with a V-DASH score ≥4, the probability of AF occurrence was 97.34%. The V-DASH score demonstrated exceptional predictive capability (area under the curve, 0.90; 95% CI, 0.79–1.00), calibration ability (Hosmer-Lemeshow goodness-of-fit P=0.552), and accuracy (sensitivity 87.50% and specificity 83.94%), surpassing other clinical scores such as the C2HEST score. Conclusions: The V-DASH score emerged as a robust predictor of AF incidence in patients with cardiac implantable electronic devices, with the highest risk observed in those with a V-DASH score ≥4. The potential clinical utility of the V-DASH score in this patient population warrants further investigation.ROC curve for predicting AFPerformance calibration plot

23 March 2026 in Cureus
Verified
Journal Article
Open access
PDF file
WTWichid Thirakraisri
Wichid Thirakraisri
TSThipsukhon Sathapanasiri
Thipsukhon Sathapanasiri
PPPariwat Pengkaew
Pariwat Pengkaew
SJSurachat Jaroonpipatkul
Surachat Jaroonpipatkul
SSSutham Sutheerapatranont
Sutham Sutheerapatranont
Background and objective Atrial high-rate episodes (AHREs) are subclinical atrial tachyarrhythmias detected by cardiac implantable electronic devices (CIEDs). Identifying strategies to reduce AHRE occurrence is clinically relevant. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are commonly prescribed for cardiometabolic conditions, and their potential role in subclinical atrial arrhythmias remains to be clarified. The objective of this study is to compare the incidence of AHREs and major adverse cardiovascular events (MACE) between SGLT2i users and nonusers among CIED patients. Methods This retrospective cohort study included CIED recipients from January 2020 to December 2024. Patients were categorized into two groups based on SGLT2i exposure. Clinical characteristics, device parameters, and AHRE data were collected and analyzed. MACE were also recorded. Multiple imputation was applied for missing left ventricular ejection fraction and left atrial volume index data. Propensity score overlap weighting was used to balance baseline covariates. Cox proportional hazards models estimated HRs for AHREs and MACE. Results A total of 123 patients with CIEDs were included, with a mean age of 73.3 ± 13.1 years, and 46.3% were male. Of these, 15 patients received SGLT2i. Overlap propensity score weighting was applied. During follow-up, AHREs occurred in three patients (SGLT2i group) and 54 patients (non-SGLT2i group), corresponding to weighted incidence rates of 40.8 and 1304.9 per 1,000 person-years, respectively. SGLT2i use was associated with a significantly lower risk of AHRE occurrence (HR 0.32, 95% CI 0.10-0.98, p = 0.03). For MACE, three events were observed in the SGLT2i group and 20 in the non-SGLT2i group, yielding a weighted HR of 1.10 (95% CI 0.25-4.96, p = 0.10). Kaplan-Meier survival analysis demonstrated significantly higher AHRE-free survival among patients receiving SGLT2i (log-rank p = 0.03), whereas MACE-free survival did not differ significantly between the groups (p = 0.10). The duration of the longest single AHRE episode was numerically shorter among SGLT2i users, although the difference was not statistically significant. Conclusions SGLT2i use was associated with a significantly lower risk of AHRE occurrence among CIED recipients, suggesting a potential reduction in subclinical atrial arrhythmia burden. However, no significant difference in MACE was observed. These findings highlight a possible antiarrhythmic benefit beyond established cardiovascular effects. Larger prospective studies are warranted to confirm these results.